Type 1 diabetes (T1D) is an autoimmune condition in which the body’s immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. Once diagnosed, individuals require lifelong insulin therapy, and managing the disease imposes a significant daily burden. However, a growing body of research shows that T1D does not appear suddenly—it develops over months or years, with a prodromal phase marked by detectable autoantibodies and metabolic changes. This preclinical window offers a critical opportunity for prediction and, ultimately, prevention. The Juvenile Diabetes Research Foundation (JDRF) has placed data-driven approaches at the center of its strategy to accelerate early detection, refine risk models, and design interventions that could delay or even stop T1D before clinical onset.

The Expanding Role of Data in T1D Prediction

Modern biomedical research is generating unprecedented volumes of data, from genomic sequences to continuous glucose monitor readings, from electronic health records to exposome measurements. For T1D, synthesizing these disparate data streams is the key to understanding the complex interplay of genetic susceptibility, immune dysregulation, and environmental triggers. JDRF has recognized that traditional risk models, which relied on family history or single genetic markers, are no longer sufficient. Instead, the foundation of T1D prediction is shifting toward integrative, multi-modal data analysis that captures the full disease trajectory.

Genetic Data and Polygenic Risk Scores

Genetic factors contribute approximately 50% of the risk for developing T1D, with over 60 identified susceptibility loci, most prominently the HLA region on chromosome 6. However, individual gene variants have limited predictive power. The advent of polygenic risk scores (PRS) aggregates the effects of thousands of common genetic variants into a single metric. JDRF-funded studies have refined PRS for T1D, enabling researchers to stratify populations by risk level far more accurately than using HLA typing alone. For example, a high PRS combined with the presence of one or more islet autoantibodies dramatically increases the likelihood of progression to clinical T1D within five years. These genetic tools are now being deployed in large-scale screening programs, such as the JDRF-supported Global T1D Registry, which collects genetic and clinical data from thousands of participants to validate and improve risk models.

Immune Monitoring and Biomarkers

The appearance of islet autoantibodies—against insulin, GAD65, IA-2, or ZnT8—is the strongest known predictor of T1D. Monitoring the number, type, and persistence of these autoantibodies provides a dynamic picture of autoimmune activity. Data-driven approaches now go beyond simple serology. High-parameter flow cytometry, single-cell RNA sequencing, and proteomic profiling are generating immune signatures that correlate with the rate of beta-cell decline. JDRF has invested heavily in longitudinal cohorts like TrialNet (a JDRF-co-founded network) and the Environmental Determinants of Diabetes in the Young (TEDDY) study, which collectively track tens of thousands of at-risk individuals from infancy. Machine learning models applied to these rich datasets have identified novel biomarkers, such as specific T-cell receptor clonotypes and cytokine patterns, that precede seroconversion by years. These discoveries are enabling researchers to design prevention trials that target the precise immune pathways activated in each individual.

Environmental and Lifestyle Factors

Genetics alone cannot explain the rising incidence of T1D, especially in younger populations. Environmental factors—viral infections, dietary habits, gut microbiome composition, vitamin D levels, and exposure to toxins—are thought to trigger or accelerate autoimmunity in genetically susceptible individuals. Data from wearable devices, continuous glucose monitors, and mobile health apps now allow researchers to collect real-time environmental and lifestyle data at an unprecedented granularity. JDRF is supporting projects that integrate these data streams with genetic and immune data using artificial intelligence. For example, the JDRF Data and AI Consortium is creating models that incorporate seasons, geographical location, and dietary records to predict windows of increased risk. Early results suggest that combining environmental triggers with genetic risk scores can improve prediction accuracy by 15–20%, moving closer to a truly personalized risk assessment.

JDRF's Strategic Investments in Data-Driven Research

JDRF’s commitment to data-driven approaches extends beyond funding individual studies. The foundation has built an ecosystem of platforms, partnerships, and initiatives that amplify the power of data across the entire T1D research community. By lowering barriers to data sharing, standardizing data formats, and promoting open science, JDRF is accelerating the translation of big data insights into clinical tools.

Funding Machine Learning and AI Models

Artificial intelligence, particularly deep learning and ensemble methods, has proven exceptionally adept at finding patterns in high-dimensional biomedical data. JDRF has awarded competitive grants to teams applying AI to T1D prediction. One notable project uses recurrent neural networks to model the temporal progression of autoantibodies and metabolic markers from longitudinal TrialNet data. Another leverages natural language processing to extract T1D risk factors from unstructured electronic health records. These models have achieved area-under-the-curve (AUC) values above 0.90 for predicting progression within three years, rivaling the performance of oral glucose tolerance tests. JDRF also supports the T1D Risk Calculator, a publicly available online tool that uses machine learning to provide a personalized risk estimate based on age, family history, genetic markers, and autoantibody status. This tool is used in clinical practice and screening programs to guide follow-up and counseling.

Collaborative Data Platforms

Data silos are a major impediment to progress. JDRF has championed the creation of federated data platforms that allow researchers to query and analyze pooled datasets without moving sensitive patient information. The JDRF Global Data Hub is a cloud-based infrastructure that harmonizes data from TrialNet, TEDDY, the Type 1 Diabetes Exchange, and international registries. The hub uses common data models and application programming interfaces (APIs) to enable cross-study analyses. For instance, a researcher can ask how gut microbiome diversity at age one affects the rate of progression in children with a high PRS—and receive answers aggregated across multiple cohorts. JDRF also funds the Phenotype to Prevention (P2P) Platform, which combines clinical, genomic, and environmental data to prioritize new drug targets for prevention. These platforms reduce duplication of effort and increase statistical power, especially for rare subgroups.

Precision Prevention Initiatives

As risk models become more accurate, the next challenge is translating predictions into effective interventions. JDRF is investing in precision prevention trials that match therapies to individual risk profiles. For example, individuals with high genetic risk but no autoantibodies may benefit from lifestyle modifications or immunomodulatory vaccines, while those who have already developed multiple autoantibodies may be candidates for biologics such as teplizumab (a CD3-targeted antibody approved for delaying T1D). JDRF’s Precision Prevention Program uses data-driven algorithms to select the most promising intervention for each participant based on their unique biomarker and genetic signature. Early-phase trials are underway testing the efficacy of oral insulin, verapamil, and other agents in precisely defined subpopulations. The goal is to move away from the one-size-fits-all prevention model and toward tailored strategies that maximize benefit and minimize exposure to unnecessary treatments.

Overcoming Challenges in Data Integration and Analysis

Despite the promise, integrating heterogeneous data sources for T1D prediction presents formidable challenges. JDRF is actively addressing these hurdles through technical standards, ethical frameworks, and community building.

Data Privacy and Ethical Considerations

Collecting genetic, immune, and environmental data raises significant privacy and equity concerns. Participants in JDRF-supported studies must trust that their sensitive information is protected and used responsibly. JDRF requires all funded projects to adhere to strict data governance policies, including de-identification, secure storage, and transparent consent processes. The foundation also funds research into privacy-preserving technologies such as federated learning and differential privacy, which allow models to be trained without accessing raw data. Additionally, JDRF is engaged in community outreach to ensure that diverse populations are represented in data collection efforts. Overreliance on data from individuals of European ancestry could lead to biased risk models that underperform in other ethnic groups. JDRF’s Health Equity in T1D Data initiative works with community health centers in underserved areas to recruit participants and collect culturally relevant environmental data.

Standardization and Interoperability

Data collected across different studies often use different formats, measurement scales, and variable definitions, making aggregation difficult. JDRF has invested in the development of common data elements (CDEs) for T1D research, in partnership with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). These CDEs cover essential variables such as autoantibody titers, HbA1c, C-peptide levels, and environmental exposures. Researchers who follow the CDE standards can more easily contribute their data to the Global Data Hub. JDRF also supports the T1D Ontology Project, which creates a formal vocabulary for T1D concepts, enabling natural language processing and automated reasoning across datasets. These efforts reduce data harmonization time from months to days and improve the reproducibility of predictive models.

The Future Landscape: From Prediction to Prevention

Data-driven prediction is not an end in itself. The ultimate vision is to implement prevention strategies at scale, identifying individuals at risk early enough to intervene before beta-cell damage becomes irreversible. JDRF’s roadmap includes several key milestones over the next decade.

Early Intervention Trials and Screening Programs

JDRF advocates for universal screening for T1D autoantibodies in children, similar to newborn screening for metabolic disorders. Pilot programs in multiple countries have demonstrated that screening followed by education and monitoring is feasible and cost-effective. Data from these screens feed back into risk models, improving their accuracy. Several large-scale intervention trials are now recruiting participants identified through screening. For instance, the JDRF- and NIDDK-funded T1D Prevention Network is testing a combination of immune-modulating agents in autoantibody-positive children. The trial uses a Bayesian adaptive design that updates treatment assignment based on accumulating biomarker data, a data-driven approach that increases efficiency. If successful, these trials will establish evidence for the first regulatory-approved prevention therapies.

Wearable Technology and Continuous Monitoring

The proliferation of consumer wearables offers a new frontier for T1D prediction. Devices that track heart rate, sleep, physical activity, and even glucose levels (via non-invasive sensors) can provide continuous insights into physiological states that precede dysglycemia. JDRF is funding studies that use wearables to detect subtle shifts in glucose variability or autonomic nervous system function that may signal impending autoimmune activation. Machine learning models trained on these high-resolution time series data can issue risk alerts weeks or months before autoantibodies become detectable. One JDRF-supported project at the University of Washington is developing a smartwatch app that integrates with environmental sensors to predict T1D onset in genetically susceptible teenagers. The combination of passive data collection and active risk models could revolutionize screening, making it accessible to anyone with a smartphone.

The Road Ahead: Data-Driven Hope for T1D Prevention

JDRF’s unwavering commitment to data-driven science has already transformed the T1D research landscape. Polygenic risk scores, autoantibody panels, and AI-based prediction models are moving from the lab into clinical practice. Collaborative platforms have broken down data silos, enabling discoveries that no single study could achieve. The challenges of privacy, equity, and standardization are being addressed through thoughtful governance and technological innovation. And the pipeline of prevention trials, grounded in precise risk stratification, offers genuine hope that the incidence of T1D can be reduced. While a cure remains the long-term goal, the ability to predict and prevent T1D will dramatically reduce the human and economic burden of this disease. With continued support from organizations like JDRF, the vision of a world without type 1 diabetes is closer than ever. For more information on JDRF’s data initiatives, visit the JDRF official website, explore the TrialNet screening program, or read about the latest NIDDK-funded T1D research.